FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

ĪĒ

				PROVAL	
Section 16. Form 4 or Form 5 obligations may continue. See	T OF CHANGES IN BENEFICIAL OWNI d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	ERSHIP	OMB Number: 3235-028 Estimated average burden hours per response: 0.1		
1. Name and Address of Reporting Person [*] Cha Albert	2. Issuer Name and Ticker or Trading Symbol <u>KalVista Pharmaceuticals, Inc.</u> [KALV]	5. Relationship of R (Check all applicabl X Director Officer (giv	le) 1) to Issuer 0% Owner other (specify	
(Last) (First) (Middle) C/O KALVISTA PHARMACEUTICALS, INC. ONE KENDALL SQUARE, BLDG 200, STE 2203	3. Date of Earliest Transaction (Month/Day/Year) 09/27/2017	below)		elow)	
(Street) CAMBRIDGE MA 02139	4. If Amendment, Date of Original Filed (Month/Day/Year)	1	t/Group Filing (Che by One Reporting by More than One	Person	
(City) (State) (Zip)					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		n of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Director Stock Option (Right to Buy)	\$6.71	09/27/2017		A		6,000		(1)	09/26/2027	Common Stock	6,000	\$0	6,000	D	

Explanation of Responses:

1. The option vests over a 12 month period: 1/12th on October 27, 2017, after which 1/12th of the total shares vest monthly, subject to continued service through each vesting date.

<u>/s/Benjamin Palleiko,</u>	
Attorney-in-Fact	

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

09/29/2017

Date